CoChat

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?

Open access
Van den Eynde, Benoit J., van Baren, Nicolas, Baurain, Jean-François · 2020 · Annual Review of Cancer Biology

Abstract

Indoleamine-2,3 dioxygenase 1 (IDO1) contributes to tumor immunosuppression by enzymatically degrading tryptophan, which is required for T cell activity, and producing kynurenine. Small-molecule inhibitors, such as epacadostat, have been developed to block IDO1 activity. In preclinical models, they can restore antitumoral T cell immunity and synergize with immune checkpoint inhibitors or cancer vaccines. Based on encouraging clinical results in early phase trials, a randomized phase III study (ECHO-301/KN-252) was launched in metastatic melanoma to test the benefit of adding epacadostat to the reference pembrolizumab therapy. The result was negative. We briefly review the clinical trials that investigated epacadostat in cancer patients and discuss possible explanations for this negative result. We end by suggesting paths to resume clinical development of compounds targeting the IDO1 pathway, which in our view remains an attractive target for cancer immunotherapy.

Overview

Integrity signals

Registry

Crossref · 10.1146/annurev-cancerbio-030419-033635

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 63 references

Research works printed but not linked: 3

  1. Comin-Anduix B, 2016, OncoTargets Ther, 9, 1767
  2. Luke JJ, 2017, J. Immunother. Cancer, 5, O41
  3. Reardon DA, 2017, Neuro-Oncology, 19

Cited by

See all 181

Metadata

Authors
Van den Eynde, B. J., van Baren, N., & Baurain, J.-F.
Affiliations
  • Ludwig Institute for Cancer Research, Brussels B-1200, Belgium;
  • de Duve Institute, Université catholique de Louvain, Brussels B-1200, Belgium
  • Cliniques Universitaires Saint-Luc (BE)
Venue
Annual Review of Cancer Biology
Published
2020-03-09
Volume
4
Issue
1
Pages
241-256
ISSN
2472-3428 (ISSN-L)
OpenAlex
W2989750739
Cited by
175
References
63
Citations by year
2026: 7 · 2025: 19 · 2024: 30 · 2023: 28 · 2022: 39 · 2021: 41 · 2020: 9
FWCI
2.29
Type
journal article
Language
en
Open access
Locations
  • Annual Review of Cancer Biology (publishedVersion, cc-by)
  • Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
IDO1 inhibitors, epacadostat, indoleamine 2,3-dioxygenase, melanoma, cancer immunotherapy, tryptophan degradation, kynurenine, tumor immunosuppression, pembrolizumab, immune checkpoint inhibitors, clinical trial failure, small molecule inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma? https://app.cochat.ai/papers/10.1146/annurev-cancerbio-030419-033635
The paper
Van den Eynde, B. J., van Baren, N., & Baurain, J.-F. (2020). Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma? Annual Review of Cancer Biology. https://doi.org/10.1146/annurev-cancerbio-030419-033635

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.